Comparison of infectious complications with BCMA-directed therapies in multiple myeloma - Summary - MDSpire

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

  • By

  • Karthik Nath

  • Tala Shekarkhand

  • David Nemirovsky

  • Andriy Derkach

  • Bruno Almeida Costa

  • Noriko Nishimura

  • Tasmin Farzana

  • Colin Rueda

  • David J. Chung

  • Heather J. Landau

  • Oscar B. Lahoud

  • Michael Scordo

  • Gunjan L. Shah

  • Hani Hassoun

  • Kylee Maclachlan

  • Neha Korde

  • Urvi A. Shah

  • Carlyn Rose Tan

  • Malin Hultcrantz

  • Sergio A. Giralt

  • Saad Z. Usmani

  • Zainab Shahid

  • Sham Mailankody

  • Alexander M. Lesokhin

  • May 31, 2024

  • 0 min

Share

Objective:

To assess the nature, incidence, rate, and risk factors for infectious complications in patients receiving BCMA-directed CAR-T compared to BCMA-targeted BsAb in relapsed/refractory multiple myeloma, specifically focusing on the differences between these therapies.

Key Findings:
  • A total of 256 patients were analyzed: 92 CAR-T, 55 BsAb, and 109 ADC-treated, highlighting the diverse treatment landscape.
  • The median age for CAR-T patients was 62 years, and for BsAb patients was 65 years, indicating a slightly older population for BsAb.
  • Patients treated with CAR-T had a median of 7 prior lines of therapy compared to 6 for BsAb, suggesting a more heavily pretreated cohort.
Interpretation:

The study highlights the need to understand infectious complications associated with BCMA-directed therapies, particularly given the high susceptibility of multiple myeloma patients to infections, which may inform future treatment protocols.

Limitations:
  • Retrospective design may introduce bias, particularly in patient selection and data collection.
  • Single-center study limits generalizability to broader populations.
  • Potential confounding factors not fully controlled, which may affect the reliability of the findings.
Conclusion:

Understanding the infectious risks associated with BCMA-directed therapies is crucial for optimizing treatment strategies and improving patient outcomes, emphasizing the need for further research in this area.

Original Source(s)

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

  • by Karthik Nath, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Bruno Almeida Costa, Noriko Nishimura, Tasmin Farzana, Colin Rueda, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Neha Korde, Urvi A. Shah, Carlyn Rose Tan, Malin Hultcrantz, Sergio A. Giralt, Saad Z. Usmani, Zainab Shahid, Sham Mailankody, Alexander M. Lesokhin

  • May 31, 2024

Related Content

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

Differential expression of immune activation markers in T cells from patients with multiple myeloma

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min